Digest Network Come funziona
Network
/
Società
Su
Non verificato

Summit Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

51 comunicati stampa

Guarda tutti i comunicati
25/10/2026
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
23/10/2026
Sanità
Scienza
Farmaceutica
Tecnologie Varie
Oncologia
Software
Tecnica
Management
Medicina - Varie
Igiene alimentare
Biotecnologia
Salute
Industria
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
22/10/2026
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Industria
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
21/10/2026
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato del lavoro
Eventi
Industria
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
19/10/2026
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
Industria
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
05/10/2026
Mercato del lavoro
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
02/10/2026
Mercato del lavoro
Scienza
Medicina - Varie
Sanità
Biotecnologia
Farmaceutica
Salute
Oncologia
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
28/09/2026
Mercato del lavoro
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Oncologia
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
22/09/2026
Industria
Eventi
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Oncologia
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0
15/09/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Fonte
Summit Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0